Advertisement

Gastro-News

, Volume 6, Issue 5, pp 43–50 | Cite as

Komplikationen chronisch entzündlicher Darmerkrankungen

Perianale Fisteln bei Morbus Crohn

  • Max ReinshagenEmail author
zertifizierte fortbildung
  • 1 Downloads

Zusammenfassung

Perianale Fisteln sind eine häufige Komplikation des Morbus Crohn. Da es derzeit keine Heilung für den Morbus Crohn gibt, besteht die Behandlung in der Gabe antientzündlicher Medikamente zur Vermeidung neuer Krankheitsschübe, um eine weitere Ausbreitung der Fistelgänge zu vermeiden. Bei vielen Patienten werden chirurgische Eingriffe erforderlich, die bei komplexen Fisteln mit diversen Abzweigungen aber nicht immer zum Ziel führen.

Literatur

  1. 1.
    Jiang H, Shen J, Ran Z Epithelial-mesenchymal transition in Crohn's disease. Mucosal Immunol 2018;11:294–303CrossRefGoogle Scholar
  2. 2.
    Park SH, Aniwan S, Scott Harmsen W, Tremaine WJ, Lightner AL, Faubion WA, Loftus EV. Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Schwartz DA et al. Inflamm Bowel Dis 2019;25:1054–1060CrossRefGoogle Scholar
  3. 3.
    Göttgens KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, Oostenbrug LE, Jonkers DM, Stassen LP, Masclee AA, Pierik MJ, Breukink SO. Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort. Eur J Gastroenterol Hepatol 2017;29:595–601CrossRefGoogle Scholar
  4. 4.
    Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. Inflamm Bowel Dis 2019;25:1227–1236CrossRefGoogle Scholar
  5. 5.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–85CrossRefGoogle Scholar
  6. 6.
    Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940–948CrossRefGoogle Scholar
  7. 7.
    Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ, Jairath V. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018;16:1879–1892CrossRefGoogle Scholar
  8. 8.
    Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016;388:1281–90CrossRefGoogle Scholar
  9. 9.
    Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology 2018 Apr;154(5):1334–1342.e4. doi:  https://doi.org/10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.CrossRefGoogle Scholar
  10. 10.
    Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology 2018;154:1334–1342CrossRefGoogle Scholar
  11. 11.
    Legué C, Brochard C, Bessi G, Wallenhorst T, Dewitte M, Siproudhis L, Bouguen G. Outcomes of Perianal Fistulising Crohn's Disease Following Anti-TNFa Treatment Discontinuation. Inflamm Bowel Dis 2018;24:1107–1113CrossRefGoogle Scholar
  12. 12.
    Burke JP. Role of Fecal Diversion in Complex Crohn's Disease. Clin Colon Rectal Surg 2019 Jul;32(4):273–279CrossRefGoogle Scholar
  13. 13.
    Dozois EJ, Lightner AL, Mathis KL, Chua HK, Kelley SR, Fletcher JG, Dietz AB, Friton JJ, Butler GW, Faubion WA. Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas. Dis Colon Rectum 2019; 62:615–622CrossRefGoogle Scholar
  14. 14.
    Serrero M, Grimaud F, Philandrianos C, Visée C, Sabatier F, Grimaud JC. Long-term Safety and Efficacy of Local Microinjection Combining Autologous Microfat and Adipose-Derived Stromal Vascular Fraction for the Treatment of Refractory Perianal Fistula in Crohn's Disease. Gastroenterology 2019;156, 2335–2337CrossRefGoogle Scholar
  15. 15.
    Dige A, Hougaard HT, Agnholt J, Pedersen BG, Tencerova M, Kassem M, Krogh K, Lundby L Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease.. Gastroenterology 2019;156, 2208–2216CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Medizinische Klinik IKlinikum BraunschweigBraunschweigDeutschland

Personalised recommendations